Scholarlink

<p>Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (<i>p</i> &lt; 0.001), and WBRT decreased (<i>p</i> = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (<i>p</i> &lt; 0.011). Overall survival (OS) did not improve in the entire cohort (<i>p</i> = 0.260); however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively; <i>p</i> = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (<i>p</i> &lt; 0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Temporal evolution of breast cancer brain metastases treatments and outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月20日

查看全文
  • Michele Bottosso,
  • Gaia Griguolo,
  • Severine Guiu,
  • Maria Cristina Guarascio,
  • Caroline Bailleux,
  • Federica Miglietta,
  • Anna Chiara Cattelan,
  • Christian Zurlo,
  • Jean-Marc Ferrero,
  • Vittoria Aldegheri,
  • Cristina Falci,
  • Francesca Zanghì,
  • Carlo Alberto Giorgi,
  • Alessandro Parisi,
  • Grazia Maria Vernaci,
  • Fabio Girardi,
  • William Jacot,
  • Maria Vittoria Dieci,
  • Amélie Darlix,
  • Valentina Guarneri

摘要

Brain metastases (BMs) are a common complication of advanced breast cancer (BC), and their management has significantly evolved. We evaluated the clinical impact of these changes dividing patients diagnosed with BCBMs at three Institutions according to year of BMs diagnosis: 2000-2007 (group A), 2008-2014 (group B) and 2015-2022 (group C). Stereotactic radiotherapy increased (p < 0.001), and WBRT decreased (p = 0.010) over time. Among HER2+ BC patients, more received anti-HER2 therapy after BM diagnosis in recent years (p < 0.011). Overall survival (OS) did not improve in the entire cohort (p = 0.260); however, OS improved in patients with HR-/HER2+ BC (median OS 8.7, 10.1, 23.7 months in group A, B, C, respectively; p = 0.002). HER2-positivity, not prognostic in group A, became prognostic in group C (p < 0.001). While therapy for patients with BCBMs significantly changed over two decades, an OS improvement was observed only in HR-/HER2+ patients, potentially due to increased availability of anti-HER2 therapies with intracranial activity.